J. B. Chemicals & Pharmaceuticals
BSE:506943 Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
WA
Consensus Narrative from 13 Analysts
Azmarda's Growth And CDMO Expansion Will Fuel Strong Revenue And Margin Growth
Key Takeaways Strong cardiology market growth and strategic product positions signal potential revenue boosts and improved market standing. Expansion in CDMO and geographic reach could enhance earnings, backed by cost optimization and high-margin product strategies.
View narrative₹2.19k
FV
26.8% undervalued intrinsic discount13.72%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
23 days ago author updated this narrative